Pfizer (PFE)

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...

Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.

Grail and Veeva Systems could be well insulated from near-term headwinds.

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

The company is entering what could be a particularly challenging period.

D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps.

Buffett thinks many stocks are too hot to touch right now, but these three aren't.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

A couple of the stocks on this list pay more than 6% in dividends.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.

Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.

Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.

Put your money to work generating dividend income with these stocks.

Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.

The crowd is looking at the next couple of years. It should be looking five years into the future.

There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.

These stocks offer juicy yields and attractive risk-reward profiles.

With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.